Hugel (145020) Q2 2026 earnings summary

Executive summary

• Net sales reached KRW 137.9bn in 2Q26, up 25.1% year-over-year.

• Net income increased 17.1% year-over-year to KRW 44.7bn.

• Operating profit was KRW 56.0bn, nearly flat year-over-year.

• Revenue for the half-year ended June 30, 2026, was KRW 254.5 billion, with 57.8% from toxin products and 25.9% from fillers/skin boosters.

• Major shareholder is Aphrodite Acquisition Holdings LLC, holding 43.53% of shares.

Financial highlights

• Gross profit rose 22.1% year-over-year to KRW 105.8bn, with a gross margin of 76.7%.

• SG&A expenses increased 66.0% year-over-year to KRW 49.7bn.

• Pre-tax income grew 15.4% year-over-year to KRW 61.4bn.

• Operating income for H1 2026: KRW 103.7 billion; net income: KRW 85.3 billion.

• Cash and cash equivalents at June 30, 2026: KRW 259.6 billion.

Outlook and guidance

• International sales mix increased to 67%, reflecting strong overseas demand.

• Continued focus on expanding global market share, especially in the US, Europe, and China.

• New product launches and regulatory approvals in multiple countries expected to drive future growth.

• Ongoing investment in R&D and product pipeline, including next-generation botulinum toxin and skin booster products.

• Botulinum toxin segment expected to continue driving growth, with 61% of sales mix.